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Introduction
After breast-conserving strategy, 10%-15% of patients experience local/regional recurrence [1] , probably partly because of the development of a radiation-resistant tumour cell population [2] . Identifying post-radiotherapy local-regional recurrence (LRR) risk factors is a major challenge, as it was clearly demonstrated that patients experiencing LRR were at higher risk of metastases and had poorer overall survival (OS) than patients achieving long-term local control [3] .
Gene expression profiling has been developed in the recent years, improving the understanding of patients' individual risk. Early breast cancer (BC) decisional algorithms are currently partly based on these analyses, since five molecular subtypes with different prognosis and/or different responsiveness to systemic treatments could be identified [4, 5] . In the metastatic setting, the DNA mutation and/or expression profile allows the identification of genomic molecular alterations resulting in proteins abnormal function, and might be interesting to select targeted agents directed against these activated enzymes [6] . This process was the primary objective of the ProfiLER clinical trial, aiming at establishing a simple genetic profile of metastatic cancers in order to offer patients personalized molecular targeted therapies. In the BC area, the genomic profiling of a population who ultimately became metastatic, and its correlation with the patient outcome years after the LRR, provides an opportunity to identify post hoc biomarkers of the initial radiation resistance, in patients who have had optimal treatments.
The aim of the present study was to determine whether specific tumour genetic alterations were associated with radiation resistance, defined as a local relapse despite optimal surgery, radiotherapy (RT and systemic adjuvant therapies, in a ProfiLER series.
Methods and materials
The present study was conducted at Leon Berard Cancer Center, France. The institutional review board approved the study, which was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided a written informed consent before enrolment.
Patient population
A total of 2036 metastatic cancer patients were prospectively included in the ProfiLER trial (NCT01774409) between January 2013 and March 2016. Patients' eligible for the present study was searched in the ProfiLER database. Patients initially diagnosed with a proven non-metastatic BC, treated with mastectomy and adjuvant RT were selected.
Clinical data and outcome
Medical records of patients were retrospectively reviewed. Patient, tumour and treatment characteristics were collected. BC LRR was defined by the occurrence of a relapse in the initially irradiated field. The local-regional progression-free survival (LRPFS) was defined as the time from surgery to LRR.
Genetic data acquisition
Target genes were studied either on archival tumour sample (n ¼ 145, 99.3%) or on new biopsies of an accessible lesion (n ¼ 1, 0.7%). Genetic analysis is detailed in supplementary methods, available at Annals of Oncology online and contained:
-Research of mutations/insertions/deletions for 69 predefined cancer genes carried out by next-generation sequencing (NGS) [7] . -An analysis of gene amplifications (copy number variations, CNV) carried out on tumour DNA by microarray-based comparative genomic hybridization (CGH).
Statistical analysis
Only recurrent genetic alterations (i.e. at least with a 3% frequency, to guarantee statistical relevance) or included in a specific signalling pathway (listed hereafter) were tested for association with outcome. When gene alterations resulted in the same protein dysfunction (i.e. biallelic inactivation via mutation and deletion), data were pooled. However, the 3% threshold was never reached in these cases. Molecular alterations (amplification/deletion/mutation, even if <3%) were pooled to study the influence of specific (namely: PI3K, MAP kinases, tyrosine kinase receptors family) pathways on LRR. LRPFS was evaluated using Kaplan-Meier method for each genomic alteration. The log-rank test was used to test the interaction between LRR and genetic alterations or clinical data. A Cox proportional hazard model was used to produce hazard ratios and 95% confidence intervals. All P values were nominal without adjustment for multiple testing. Significance was defined by P < 0.05. The multivariate analysis was carried out using a Cox multivariate analysis based on the significant-or close-to-significance (P < 0. Table 1 . Radiation indications complied with international guidelines. In breast conserving surgery patients, a conventionally fractionated radiation scheme was carried out with 2 Gy per fraction for a total dose of 50 Gy in 25 daily fractions, with a subsequent radiation boost of 10-16 Gy to the tumour bed. In case of radical mastectomy, 50 Gy/25 fractions were delivered to the chest wall. A total of 104 patients, including all patients with axillary node involvement (n ¼ 87, 100%), received regional lymph nodes radiotherapy, with 46-50 Gy on the medial supraclavicular lymph nodes. The internal mammary lymph nodes were irradiated (46 Gy/23 fractions) in 75 patients [62 node-positive patients (71.3%), 13 node negative patients with internal tumours]. Axillary lymph nodes were irradiated 22 patients (25.3% of nodepositive patients), all with in massive axillary node involvement (>90% of dissected lymph nodes, or massive extracapsular extension).
LRR and outcomes
At a median follow-up of 6.5 years, 52 patients (35.6%) had died.
A LRR was reported in 55 patients (37.7%), with a median LRPFS of 16.2 years. LRR mainly occurred on the chest wall (n ¼ 29; 52.7%), in the ipsilateral breast (n ¼ 21; 38.2%) and in locoregional lymph nodes (n ¼ 5; 9.1%). History of disease and treatment of the metastatic relapse are reported in supplementary Table S2 , available at Annals of Oncology online. 
Genomic alterations
Tumour samples were obtained from the primary tumour (66.5%), lymph nodes (9.5%) or from metastatic lesions (24%, mainly with cutaneous and lung metastases). Because of insufficient tumour (DNA) material, 21 (14.4%) CGH and 11 (7.5%) NGS profiles could not be processed (Table 1) . A total of 193 genomic rearrangements were identified, with 117 gene amplifications, 31 homozygous deletion and 45 mutations (supplementary Table S3 , available at Annals of Oncology online). CGH showed nine recurrent (i.e. >3%) genes amplifications (supplementary Table S4 , available at Annals of Oncology online), mainly with CCND1 (n ¼ 19; 13%), FGFR1 (n ¼ 17; 11.6%) and MDM2 (n ¼ 9; 6.2%). One recurrent deletion was identified, on MAP2K4 (homozygous deletion, n ¼ 7; 4.8%). The NGS analysis identified seven recurrent mutations (supplemen tary Table S5 , available at Annals of Oncology online), mainly regarding TP53 (n ¼ 47; 32.2%), PIK3CA (n ¼ 31; 21.2%), PTEN [n ¼ 8; 5.5%, including biallelic mutation (n ¼ 6) and heterozygous deletion on the first allele plus mutation on the other (n ¼ 2)] and PDGFRB (n ¼ 7; 4.8%).
The association between genetic profiles and the hormone/ HER2 receptor expression was assessed. A significant correlation was assessed between PIK3CA and hormone receptors (P < 0.001), whereas no correlation was found between PIKCA and HER2 (P ¼ 0.44). PIK3CA was mutated in 28.4% (n ¼ 27) of HRþ/HER2À cancers [P ¼ 0.0008 compared with triple negative (TN) tumours] (supplementary Tables S4 and S5 , available at Annals of Oncology online). Exhaustive description of amplifications, deletions and mutations are given in supplementary Table  S3 , available at Annals of Oncology online.
Genetic alterations involved in major signalling pathways were studied (supplementary Table S6 , available at Annals of Oncology online). Genes involved in the PI3 kinases pathway were frequently altered (61 alterations, assessed in 52 patients; 35.6%), mainly with PIK3CA mutation (n ¼ 31; 21.2%). Genes involved in the tyrosine kinases receptors family were often altered (70 alterations observed in 58 patients; 39.5%), mainly with FGFR1 amplification (n ¼ 17; 11.6%). Genes involved in the MAP kinases pathway were less frequently altered (eight alterations), mainly with KRAS amplification (n ¼ 5; 3.4%).
Prognosis factors of LRR: univariate analysis
No gene amplification or deletion was significantly correlated with LRR in univariate analysis. As for gene mutations, PIK3CA was associated with favourable median LRPFS, with 23.6 years for mutations carriers versus 9.9 years for wild-type patients (HR 0.27, 95% CI 0.12-0.65, P ¼ 0.002, Figure 1 ). The PIK3CA mutation was a protective factor of LRR for HRþ patients (HR 0.28, 95% CI 0.10-0.82, P ¼ 0.01), and for HRþ/HER2À patients (HR 0.38, 95% CI 0.15-0.93, P ¼ 0.03). The hazard ratios of the HRÀ/HER2þ and HRþ/HER2þ subgroups could not be reliably statistically analysed, with only two and three patients, respectively.
Among relapsing patients, the median time to LRR was associated with the PI3CA mutation status with a close to significant difference, with 9.6 years for mutated patients versus 4.7 years for non-mutated patients (P ¼ 0.07). PDGFRB mutation was associated with a close to significant higher risk of LRR, with a median LRFS of 4.8 years for mutation carriers versus 16.1 years for wildtype patients (HR 2.2, 95% CI 0.79-6.29, P ¼ 0.12). Other recurrent mutations were not found to impact the LRR risk. Alterations of the PI3 kinases pathway (i.e. 31 PIK3CA mutations plus 30 other alterations, identified in 52 patients, supple mentary Table S6 , available at Annals of Oncology online) were a protective factor of LRR (HR 0.38, 95% CI 0.2-0.73, P ¼ 0.003). However, when the PI3 kinase pathway was studied excluding the PIK3CA mutation, alterations of the pathway were no more associated with LRR (HR 0.93, 95% CI 0.42-2.07, P ¼ 0.86). Alterations of the MAP kinases pathway (HR 0.37, 95% CI 0.05-2.71, P ¼ 0.31) or of the Tyrosine Kinase receptors family (HR 0.95, 95% CI 0.54-1.67, P ¼ 0.85) were not found to significantly influence the LRR incidence.
Regarding classical prognostic factors, TN (HRÀ/HER2À) BC was associated with a significantly higher risk of LRR when compared with HRþ/HER2À (HR 4.71, 95% CI 2.06-6.67, P < 0.001). Median LRPFS was of 17 years for the HRþ/HER2À patients versus 4.6 years for TN patients. pT3-T4 BC patients had an increased risk of LRR (HR 2.43, 95% CI 1.23-4.79, P ¼ 0.008) when compared with pT1-T2. Lymphadenectomy was associated with a lower LRR incidence (HR 0.51, 95% CI 0.27-0.98, P ¼ 0.04). Positive hormone receptors were associated with a lower LRR incidence (HR 0.34, 95% CI 0.2-0.57, P < 0.001). Capsule rupture (HR 0.83, 95% CI 0.46-1.51, P ¼ 0.5), SBR grade (HR 1.60, 95% CI 0.66-3.89, P ¼ 0.11) and vascular invasion status (HR 1.61, 95% CI 0.84-3.08, P ¼ 0.14) were non-significantly correlated to the LRR rate.
Prognosis factors of LRR: multivariate analysis
The univariate analysis provided potential (P < 0.15) LRR predictive factors, with cancer hormonal/HER2 status, lymphadenectomy, SBR grade, tumour size, vascular invasion, capsule rupture, PIK3CA pathway, PDGFRB and PIK3CA mutations. Although significant in univariate analysis, the PIK3CA pathway could not be included in the multivariate analysis as it was correlated, by construction, with PIK3CA mutation. Furthermore, the cancer hormonal status was excluded from the multivariate analysis since hormone receptor status (HRþ/HRÀ) was very significantly correlated with PIK3CA mutation (P < 0.001).
The impact of these factors on LRR was thus studied using a Cox multivariate analysis (Table 2) . PIK3CA mutation was an independent protective factor of LRR (HR 0.29, 95% CI 0.09-0.99, P ¼ 0.047). Lymphadenectomy was an independent protective factor of LRR (HR 0.35, 95% CI 0.14-0.86, P ¼ 0.022). pT3-T4 was an independent risk factor of LRR (HR 2.51, 95% CI 1.10-5.74, P ¼ 0.029). Vascular invasion was independent risk factor of LRR (HR 2.12, 95% CI 1.04-4.31, P ¼ 0.038). Furthermore, PIK3CA status was associated with OS in the whole set of patients, with a median OS of 24.4 years for mutated patients and 15.9 years for non-mutated patients (HR 0.39, 95% CI 0.39-0.84, P ¼ 0.01). Significant association of PIK3CA with OS was not identified anymore when specific hormone subgroups were studied: HR 0.5, 95% CI 0.2-1.2, P ¼ 0.17 in HRþ patients, HR 0.5, 95% CI 0.21-1.2, P ¼ 0.115 in HRþ/HER2À patients.
Discussion
The molecular predictive factors for local relapse of BC after optimal surgery and RT were retrospectively investigated in the ProfiLER study dataset, as pre-specified in the protocol. We observed a strong impact of PIK3CA mutation on the date of LRR, with better LRPFS for PIK3CA-mutated patients. To our knowledge, the present predictive biomarkers of local response are reported for the first time in BC patients experiencing optimal treatment. The mutation frequencies observed in our series were consistent with the COSMIC database [8] and literature [9] [10] [11] .
However, several limitations should be underlined. The selection bias of the study (including only metastatic patients) implied an enrichment in the observed risk of local relapse, which was indeed reported. Furthermore, the fact of mixing patients with different LRR rates (neoadjuvant chemotherapy patients, adjuvant chemotherapy patients) created a heterogeneous population and poses the problem of the a posteriori interpretation of the LRR. Finally, the results obtained from genomic analyse of different sources including metastases (probable tumour heterogeneity) and also the fact that NGS profiles could not be processed in 7.5% of patients' poses an additional problem in the interpretation of the results. A prospective analysis based on a homogeneous population should be conducted soon by the same team in order to avoid such limitations. Finally, survival differences and especially the ones in relation with HER2/HR (including TN tumour patients) status should be considered with great caution because of the limited number of patients.
The phosphatidylinositol 3'-kinase (PI3K) pathway regulates cell growth, proliferation, and apoptosis. The class I PI3K enzyme is partly composed by a catalytic subunit (p110), encoded by the PIK3CA gene. When activated (e.g. through tyrosine kinase receptors such as HER2), the PI3K enzyme plays a leading role in the aforementioned cellular processes, stimulating the AKT pathway. In BC patients, the impact of PIK3CA mutations on PFS and OS after RT is still debated due to inconsistent results. A recent meta-analysis including 5719 BC patients suggested that PIK3CA mutations were associated with an increased relapse-free survival (HR 0.76, 95% CI 0.59-0.98, P ¼ 0.03) but had no beneficial effect on OS [12] . In early BC, PIK3CA mutations correlated to favourable general outcomes in the sub-population of oestrogen receptor-positive (ERþ) early stage BC [12, 13] . Regarding advanced BC, no reliable data have been published yet but an association with a decreased OS was suggested [14] . To date, the signification of the PIK3CA mutation in BC is therefore unclear and the biological mechanisms linking PIK3CA mutation, global outcomes and local recurrence are still unknown. It is hypothesized that local relapse and radiosensitivity might be influenced by PIK3CA mutation, possibly due to increased hormone receptors positivity, as it is observed in the present study [12, 15] . In a recent systematic review of 26 BC clinical studies, PIK3CA mutations were significantly associated with positivity of oestrogen (OR 1.92, 95% CI 1.65-2.23, P < 0.001) and progesterone receptors (OR 1.88, 95% CI 1.61-2.20, P < 0.001) [12] . In term of hormone receptors status, the present study therefore corroborates these results, with a very significant association between hormone receptor positivity and PIK3CA mutation (P < 0.001). In term of HER2 status, literature is more controversial, with studies either suggesting that PIK3CA mutation is associated with HER2 overexpression, with HER2 negativity, or that PIK3CA is not associated with HER2 status [14] . Only the association between PIK3CA mutation and luminal type (HR-positive/HER2-negative) tumour seem well established [14] . In the present set of patients, HER2 status was not associated with PIK3CA mutation (P ¼ 0.44), but most of PIK3CA mutated patients did have luminal-type (HR-positive/HER2-negative) tumours (n ¼ 27, 87.1%). The interaction between hormone receptors, PIK3CA, and LRFS is probably multifactorial, as crosstalks between PI3K pathway and hormone receptors have been suggested in preclinical data [16] , as well as a radiosensitivity modulation by hormone receptors [17, 18] . Pre-clinical data also suggested that the PIK3CA mutation directly modulated the tumour radiosensitivity through yet unclear phenomena [19, 20] . To our knowledge, the clinical impact of PIK3CA mutation in local outcomes of BC patients was only reported in sub-optimally managed patients treated in the 70s [21] . PIK3CA mutations were associated with approximately half the risk for LRR in comparison with wildtype patients (P ¼ 0.07) when adjusting for other prognostic factors [21] . A protective influence of PIK3CA mutation on LRR was reported in the present study, suggesting a radio-sensitizing effect in a large cohort of BC patients. Interestingly, LRR seemed delayed for PIK3CA mutated patients, rather than avoided (Figure 1 ), suggesting that most of metastatic BC patients would experience LRR, if they lived long enough. Tumour genetic profiling has transformed the understanding and management of local and metastatic cancers, guiding patient treatment towards personalized targeted therapies. However, the genetic alterations that are discovered through such research might provide novel insights into the individual risk of local relapse. The present findings suggest that PIK3CA might be a central element modulating the efficacy of BC radiotherapy and should be explored in additional datasets. Although the 'classical' prognostic factors remain the basis of the selection of patients before the tumour biology, in the era of gene profile, these results might lead the way to a tailored radiotherapy in patients with radio-sensitizing mutations, identifying a subpopulation eligible for a dose or volume de-escalation. However, the confirmation of the impact of PIK3CA mutation must go through a rigorous selection of patients to avoid the bias and confusion of the importance of well-established parameters (hormone receptors, clinical prognostic factors) compared with tumour biology.
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